The use of GP IIb/IIIa inhibitors into new perspectives: Pre-catheterization laboratory administration

European Heart Journal, Supplement

Volumn 7, Issue I, 2005, Pages

  Beygui, Farzin ^a   Montalescot, Gilles ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Faciliatated PCI; Gp IIb IIIa inhibitors; Primary PCI

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; TENECTEPLASE; TIROFIBAN;

BLEEDING; CARDIOGENIC SHOCK; CLINICAL TRIAL; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYSIS; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART VENTRICLE FIBRILLATION; HUMAN; LABORATORY; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPERFUSION; REVIEW; RISK ASSESSMENT; ST SEGMENT ELEVATION; STROKE;

EID: 26844535258     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui062     Document Type: Review

References (46)

1. The Reperfusion Therapy Consensus Group. Selection of reperfusion therapy for individual patients with evolving myocardial infarction. Eur Heart J 1997;18:1371-1381.
2. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20.
3. Dalby M, Bouzamondo A, Lechat P et al. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation 2003;108:1809-1814.
4. Andersen HR, Nielsen TT, Rasmussen K et al.; DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349:733-742.
5. Steg PG, Bonnefoy E, Chabaud S et al.; Comparison of Angioplasty and Prehospital Thrombolysis In acute Myocardial infarction (CAPTIM) Investigators. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003;108:2851-2856.
6. Bonnefoy E, Lapostolle F, Leizorovicz A et al.; Comparison of Angioplasty and Prehospital Thromboysis in Acute Myocardial Infarction Study Group. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002;360:825-829.
7. Cannon CP, Gibson CM, Lambrew CT et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000;283:2941-2947.
8. Antoniucci D, Valenti R, Migliorini A et al. Relation of time to treatment and mortality in patients with acute myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol 2002;89:1248-1252.
9. De Luca G, Suryapranata H, Zijlstra F et al.; ZWOLLE Myocardial Infarction Study Group. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2003;42:991-997.
10. Boersma E, Harrington RA, Moliterno DJ et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-198.
11. Brener SJ, Barr LA, Burchenal JE et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98:734-741.
12. Neumann FJ, Blasini R, Schmitt C et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998;98:2695-2701.
13. Montalescot G, Barragan P, Wittenberg O et al.; ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
14. Tcheng JE, Kandzari DE, Grines CL et al.; CADILLAC Investigators. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2003;108:1316-1323.
15. De Luca G, Suryapranata H, Stone GW et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005;293:1759-1765.
16. Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003;41:26-32.
17. Montalescot G, Andersen HR, Antoniucci D et al. Recommendations on percutaneous coronary intervention for the reperfusion of acute STelevation myocardial infarction. Heart 2004;90:e37.
18. Reimer KA, Jennings RB. The "wavefront phenomenon" of myocardial ischemic cell death II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 1979;40:633-644.
19. Gersh BJ, Anderson JL. Thrombolysis and myocardial salvage. Results of clinical trials and the animal paradigm-paradoxic or predictable? Circulation 1993;88:296-306.
20. Cannon CP, Gibson CM, Lambrew CT et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000;283:2941-2947.
21. Brodie BR, Stone GW, Morice M-C et al. Stent Primary Angioplasty in Myocardial Infarction Study Group. Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction. Am J Cardiol 2001;88:1085-1090.
22. Berger PB, Ellis SG, Holmes DR Jr et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in acute coronary syndromes (GUSTO-IIb) trial. Circulation 1999;100:14-20.
23. De Luca G, Suryapranata H, Zijlstra F et al. ZWOLLE Myocardial Infarction Study Group. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2003;42:991-997.
24. Bax M, de Winter RJ, Schotborgh CE et al. Short- and long-term recovery of left ventricular function predicted at the time of primary percutaneous coronary intervention in anterior myocardial infarction. J Am Coll Cardiol 2004;43:534-541.
25. Beygui F, Le Feuvre C, Helft G et al. Myocardial viability, coronary flow reserve, and in-hospital predictors of late recovery of contractility following successful primary stenting for acute myocardial infarction. Heart 2003;89:179-183.
26. Stone GW, Cox D, Garcia E et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 2001;104:636-641.
27. Topol EJ, Califf RM, George BS et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987;317:581-588.
28. Rogers WJ, Baim DS, Gore JM et al.; TIMI II-A Investigators. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Circulation 1990;81:1457-1476.
29. SWIFT Trial Study Group. SWIFT trial of delayed elective intervention vs. conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. BMJ 1991;302:555-560.
30. Ross AM, Coyne KS, Reiner JS et al.; PACT Investigators. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. J Am Coll Cardiol 1999;34:1954-1962.
31. O'Neill WW, Weintraub R, Grines CL et al. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation 1992;86:1710-1717.
32. Widimsky P, Groch L, Zelízko M et al.; PRAGUE Study Group Investigators. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. Eur Heart J 2000;21:823-831.
33. Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1992;19:1065-1069.
34. Kastrati A, Mehilli J, Schlotterbeck K et al.; Bavarian Reperfusion Alternatives Evaluation (BRAVE) Study Investigators. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA 2004;291:947-954.
35. Ellis SG, Armstrong P, Betriu A et al.; FINESSE Investigators. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention. Am Heart J 2004;147:e16.
36. van't Hof AW, Ernst N, de Boer MJ et al.; On-TIME study group. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the Ongoing Tirofiban in Myocardial Infarction Evaluation (On-TIME) trial. Eur Heart J 2004;25:837-846.
37. Lee DP, Herity NA, Hiatt BL et al.; Tirofiban Given in the Emergency Room before Primary Angioplasty. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the Tirofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 2003;107:1497-1501.
38. Cutlip DE, Ricciardi MJ, Ling FS et al. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol 2003;92:977-980.
39. Zorman S, Zorman D, Noc M. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol 2002;90:533-536.
40. Arntz H-R, Schroder JF, Pels K et al. Prehospital versus periprocedural administration of abciximab in STEMI: early and late results from the randomised REOMOBILE-study. (Abstract). Eur Heart J 2003;24(suppl.):268.
41. Mesquita Gabriel H, Oliveira J, Canas da Silva P et al. Early administration of abciximab bolus in the emergency room improves microperfusion after primary percutaneous coronary intervention, as assessed by TIMI frame count: results of the ERAMI trial. (Abstract). Eur Heart J 2003;24(suppl.):543.
42. Gyongyosi M, Domanovits H, Benzer W et al.; ReoPro-BRIDGING Study Group. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion-results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. Eur Heart J 2004;25:2125-2133.
43. Zeymer U, Zahn R, Schiele R et al. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J 2005, doi: 10.1093/eurheartj/ ehi293. Published online ahead of print April 27, 2005.
44. Montalescot G, Borentain M, Payot L et al. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA 2004;292:362-366.
45. Topol EJ, Moliterno DJ, Herrmann HC et al.; TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-1894.
46. Brown DL, Fann CS, Chang CJ. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention. Am J Cardiol 2001;87:537-541.